Using nanoparticles to improve treatment for pancreatic cancer
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
This study is testing a new treatment for pancreatic cancer that uses tiny particles to deliver medicine right to the tumor while also helping the immune system fight the cancer better, with the goal of improving outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10983822 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapy for pancreatic cancer by using specially designed nanoparticles that can penetrate the dense stroma surrounding tumors. These nanoparticles are engineered to deliver cancer-fighting drugs directly to the tumor cells while also modulating the immune response to enhance treatment effectiveness. The approach involves using imaging techniques to guide the delivery of these nanoparticles, ensuring they reach the targeted areas within the tumor. By overcoming barriers that typically limit drug delivery, this research aims to improve patient outcomes in pancreatic cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who have not responded well to existing therapies.
Not a fit: Patients with early-stage pancreatic cancer or those who are not eligible for experimental treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in using nanoparticles for targeted cancer therapies, indicating that this approach could be effective.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Yang, Lily — Emory University
- Study coordinator: Yang, Lily
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.